Jason Crawford oversees drug development at Gandeeva Therapeutics by translating structural insights derived from cryo-EM and computational predictions into novel medicines. Jason held roles of increasing scientific responsibility and portfolio oversight at adMare BioInnovations (formerly CDRD), with the most senior role as Venture Partner. Prior to adMare, Jason was at AnorMED Inc. where he was a Manager of Development Chemistry and led the drug substance CMC efforts to enable pre-clinical and outsourced GMP production for AMD070 for preclinical to Phase 2 clinical trials, and for plerixafor (Mozobil) for Phase 2 through to regulatory approval. Jason also held medicinal chemistry roles at AnorMED and Microcide Inc. Jason received his BSc and PhD from the University of Victoria and conducted postdoctoral research at Ohio State University.